Long-acting beta 2-agonist (LABA)
ApprovedSmall molecule
NovartisLong-acting beta 2-agonist (LABA) is one of 43 small molecule programs targeting Allergic Asthma. It is currently in Approved.
1
Indications
2
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in Allergic Asthma
#DrugCompanyPhaseTrials
1Xolair
RochePhase 3
Antibiotics
MMelinta Therapeutics, Inc.
Approved
Xolair
RochePhase 3
Symbicort
AstraZenecaPhase 3
Levocetirizine Dihydrochloride
UCBPhase 3
Daliresp
AstraZenecaPhase 2
Tezspire
AstraZenecaPhase 2
Soliris
AstraZenecaPhase 2
EBGLYSS
Eli LillyPhase 2
Seretide
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]